Quantcast

Latest infectious disease Stories

2014-09-22 12:31:25

PINE BROOK, N.J., Sept. 22, 2014 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed three phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in development for the treatment of inhalational anthrax and data from these studies support the safety and tolerability of the antitoxin when administered intravenously...

2014-09-17 16:27:04

SAN DIEGO and PRINCETON, N.J., Sept. 17, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), disclosed today that each company will be presenting at the 2014 Exosomes & SingleCell Analysis Summit. http://photos.prnewswire.com/prnvar/20130912/LA78266LOGO On September 18(th),...

2014-09-17 12:27:55

Rebiotix microbiota-based drug candidate used to assess a non-antibiotic approach to an urgent public health threat ROSEVILLE, Minn., Sept. 17, 2014 /PRNewswire/ -- Rebiotix Inc. announced this morning that results of the Phase 2 study of the company's lead product candidate, RBX2660 (microbiota suspension) will be presented in two posters and a podium presentation during the IDWeek 2014 conference in Philadelphia from October 8-12. PUNCH CD study results will be presented during the poster...

2014-09-10 08:32:21

SAN DIEGO and NEW YORK, Sept. 10, 2014 /PRNewswire/ -- Aethlon Medical, Inc., (NASDAQ:OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The Company has launched official portals on social media channels including Facebook, Twitter,...

2014-09-08 16:25:18

Phase I/II study also demonstrated SER-109 restoration of a diverse, healthy microbiome CAMBRIDGE, Mass., Sept. 8, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced final data for its single-arm, open-label clinical trial of SER-109, its first-in-field, oral microbiome therapeutic. SER-109, a mixture of bacterial spores, is designed for the treatment of recurrent...

2014-09-08 08:31:27

SAN DIEGO and PRINCETON, N.J., Sept. 8, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that ESI researchers have developed and initially validated a lectin-based diagnostic platform that is able to isolate exosome-based biomarkers underlying a broad-spectrum of oncology indications. Aethlon Medical develops targeted therapeutic devices to address infectious disease, cancer and other...

2014-09-02 12:28:32

SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has received independent internal review board (IRB) approval to initiate human clinical studies of Hemopurifier® therapy at DaVita MedCenter Dialysis located in Houston, Texas. http://photos.prnewswire.com/prnvar/20090325/LA88762LOGO-b...

2014-08-14 20:22:23

KANSAS CITY, Kan., Aug. 14, 2014 /PRNewswire/ -- The current Ebola Virus Disease (EVD) is the deadliest on record but it is important to understand key elements of this virus. Lee Norman, MD, chief medical officer for The University of Kansas Hospital offers these 10 things to know about Ebola: 1. Cases Are Out-Migrating From Africa: This is happening due to the fact that infected or ill people are traveling out of those countries in Africa with Ebola outbreaks. Cases...

2014-08-06 12:28:09

SAN DIEGO, Aug. 6, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. http://photos.prnewswire.com/prnvar/20090325/LA88762LOGO-b The current ebola outbreak in West Africa demonstrates the urgent need for therapeutic strategies to defend against emerging pandemic threats. It also highlights why the Department of Health and Human Services (HHS) has shifted the focus of government biodefense and...

2014-07-07 10:19:43

Texas A&M Health Science Center A new test for tuberculosis (TB) could dramatically improve the speed and accuracy of diagnosis for one of the world’s deadliest diseases, enabling health care providers to report results to patients within minutes, according to a study published this week in the journal Angewandte Chemie. Jeffrey Cirillo, Ph.D., professor at the Texas A&M Health Science Center College of Medicine, in collaboration with GBDbio, a Texas A&M spinoff company,...


Latest infectious disease Reference Libraries

69_3e2a06a821d939ffdc2eab851bee21e9
2011-01-24 12:50:52

Hepatitis A, caused by hepatitis A virus, is an acute infectious disease of the liver that is transmitted person to person by ingestion of contaminated food or water or through direct contact with an infectious person. Millions of people are believed to become infected with HAV every year. The incubation period is two to six weeks and on average is 28 days. In less developed countries the HAV is usually contracted in early childhood. Clean water helps to decrease contraction of HAV. In 90%...

More Articles (1 articles) »
Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related